Oncocin Onc112 analog a
General Information
DRACP ID DRACP02698
Peptide Name Oncocin Onc112 analog a
Sequence VRKPPYLPRPRWPRrIYNr
Sequence Length 19
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
SH-SY5Y | Neuroblastoma | Blastoma | 10% Cytotoxicity=600 µg/ml | MTT assay | 24 h | 1 |
HeLa | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | 50-60% Cytotoxicity=600 µg/ml | MTT assay | 24 h | 1 |
HepG2 | Hepatoblastoma | Blastoma | <5% Cytotoxicity=600 µg/ml | MTT assay | 24 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HEK293: 50-60% Cytotoxicity=600 µg/ml
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antibacterial
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification r=D-Arg
Chiral Mix
Physicochemical Information
Formula C105H158N32O19
Absent amino acids ACDEFGHMQST
Common amino acids P
Mass 249382
Pl 12.06
Basic residues 5
Acidic residues 0
Hydrophobic residues 4
Net charge 5
Boman Index -5594
Hydrophobicity -128.42
Aliphatic Index 56.32
Half Life
/
Extinction Coefficient cystines 8480
Absorbance 280nm 471.11
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 26334348
Title Optimization of oncocin for antibacterial activity using a SPOT synthesis approach: extending the pathogen spectrum to Staphylococcus aureus
Year 2016
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
External Code
DBAASP ID DBAASPS_13596